Latest Headlines

Latest Headlines

IDRI, Wellcome Trust to take tuberculosis jab to PhIIa in South Africa

With multidrug-resistant forms of tuberculosis on the rise, and the variable efficacy of the generic BCG vaccine, it is getting harder and harder to treat the disease. The Infectious Disease Research Institute (IDRI) is stepping up to the plate and taking its TB candidate to Phase IIa trials in South Africa.

GlaxoSmithKline takes TB vaccine to Phase IIb

BCG (Bacille Calmette-Gu é rin) is the only WHO-approved tuberculosis vaccine and is given to infants, but has proven ineffective in adults. Enter GlaxoSmithKline, which, along with Aeras and Kenya Medical Research Institute, will roll their candidate in Phase IIb trials in Kenya.

Tuberculosis cocktail stirs hopes for quick cures in patients with HIV

A new three-drug combo treatment for tuberculosis better eradicated the disease than standard therapy in a midstage trial, showing particular promise for patients with HIV as it rolls into Phase III development.

Serum targets Merck, Sanofi stronghold with TB vax deal

Serum Institute of India has a history of winning shares in established vaccine markets by undercutting the competition. And now it has bought the rights to a tuberculosis vaccine it believes can beat shots by Merck and Sanofi on effectiveness, as well as cost.

Sequella scouts $38M round after nabbing Pfizer antibiotic

Rockville, MD-based Sequella has snagged global rights to a mid-stage antibiotic from Pfizer, which has been jettisoning programs that don't fit squarely into its core disciplines following a top-to-bottom restructuring of its big pipeline. And the biotech says it's on its way to rounding up a $38 million C round to fund a pivotal study for its new therapy.

Despite setback, TB vaccine study is a step in the right direction

While a closely watched study of Gates-backed TB vaccine MVA85A failed to produce the desired results to guard against infection in infants, a dozen more vaccine candidates are being tested in humans. Regardless of results, the first efficacy trial of a new TB vaccine is a milestone.

Bitter setback as TB vaccine fails to protect infants in key study

A closely watched study of a new Gates-backed tuberculosis vaccine--MVA85A--failed to deliver desperately hoped-for data that it could guard infants against the lethal disease. Investigators said the jab failed to prove that it had a comparable effect as that seen in a study involving adults.

Gates-backed TB vaccine trial faces moment of truth

The global fight against tuberculosis is about to yield some big news. Next week researchers are reporting results a mid-stage study of the leading next-generation vaccines against TB, with supporters from the Bill & Melinda Gates Foundation and elsewhere hoping for a breakthrough for populations at risk of infection.

J&J wins accelerated OK for first new TB drug in 40 years

On the last day of the year the FDA came through with a rapid-fire approval of Johnson & Johnson's bedaquiline, the first new treatment for drug-resistant tuberculosis in four decades.

TB vaccine tested in infants of HIV-positive mothers

University of Cape Town's South African Tuberculosis Vaccine Initiative and Stellenbosch's Desmond Tutu TB Centre are recruiting infants to test a new tuberculosis vaccine for newborns of HIV-positive moms, a demographic not served by the current vaccine.